Bisoprolol

Bisoprolol is a beta-blocker taken by mouth. The US label read, for bisoprolol fumarate tablets, lists one use: the management of hypertension, alone or in combination with other antihypertensive agents.

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 19484; UNII UR59KN573L. The label names the substance as bisoprolol fumarate, so UNII UR59KN573L is the UNII of the fumarate salt and is a broad match. MeSH descriptor D017298 is Bisoprolol. Class: beta-Adrenergic Blocker (FDA established pharmacologic class, RxClass). The label read is the Solco Healthcare US, LLC label for bisoprolol fumarate, application ANDA217368, effective 2023-06-26 in openFDA. openFDA lists no single-ingredient bisoprolol label under a new drug application (a search on 2026-11-08 returned only a bisoprolol and hydrochlorothiazide combination), so this generic label was read. Other generic labels were not read. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 15 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
15
Phase 3 or 4
13
Recruiting
1
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingNot yet recruitingActive, not recruitingCompletedUnknown statusAll statuses
Phase 2000202
Phase 41116413
All phases1118415

Conditions these trials study

And 3 more.

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 7 more.

About this drug

Level
Substance
Mechanism
Not reported

Classification codes

  • UNII UR59KN573L

Claims and evidence

Context People for whom the US label of bisoprolol fumarate tablets lists an indication: hypertension

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The label does not state an age range in the passage read.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passage read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Bisoprolol fumarate, in the Solco Healthcare US, LLC version dated 2023-06-26 in openFDA, lists the medicine for the management of hypertension, alone or in combination with other antihypertensive agents.

    Applies to Recipient not specified People for whom the US label of bisoprolol fumarate tablets lists an indication: hypertension

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-08
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for Bisoprolol fumarate, Solco Healthcare US, LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 084308e4-3b8b-40d6-acbf-d775772a8a73 (manufacturer Solco Healthcare US, LLC, application ANDA217368), returned on 2026-11-08. The label text is dated 2023-06-26 (effective_time). Other openFDA records of bisoprolol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], INDICATIONS AND USAGE
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2023-06-26
      Source state
      Current
      Version fingerprint
      5fad3e8635e7f8013200b11d2037d0759ef66b1362590865a526e320f258436c
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Bisoprolol fumarate, Solco Healthcare US, LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 084308e4-3b8b-40d6-acbf-d775772a8a73 (manufacturer Solco Healthcare US, LLC, application ANDA217368), returned on 2026-11-08. The label text is dated 2023-06-26 (effective_time). Other openFDA records of bisoprolol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20230626.
      Retrieved
      Source effective date
      2023-06-26
      Source state
      Current
      Version fingerprint
      5fad3e8635e7f8013200b11d2037d0759ef66b1362590865a526e320f258436c
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-08, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

ZEBETA

No label from the application holder was found in the openFDA label dataset for application NDA019982. This page does not show another labeler's label in its place.

ZIAC

No label from the application holder was found in the openFDA label dataset for application NDA020186. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA019982 ZEBETA
  2. Approval NDA020186 ZIAC

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 2

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA019982

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA020186

Registry trials 15

Record details

Record id
cardio:bisoprolol
Content hash
231afa104c185ea8c9b78c8cb2a6ab57d1ca844fa3bd6dd48816992fd02f86bb